Daily Stock Analysis, COLL, Collegium Pharmaceutical Inc, priceseries

Collegium Pharmaceutical Inc. Daily Stock Analysis
Stock Information
Open
11.39
Close
11.78
High
11.80
Low
11.30
Previous Close
11.40
Daily Price Gain
0.38
YTD High
17.60
YTD High Date
Feb 1, 2017
YTD Low
7.37
YTD Low Date
May 9, 2017
YTD Price Change
-3.90
YTD Gain
-24.87%
52 Week High
18.67
52 Week High Date
Oct 21, 2016
52 Week Low
7.37
52 Week Low Date
May 9, 2017
52 Week Price Change
-6.10
52 Week Gain
-34.12%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Sep 2. 2015
15.14
Sep 8. 2015
15.97
3 Trading Days
5.48%
Link
LONG
Sep 14. 2015
18.76
Sep 28. 2015
20.07
10 Trading Days
6.96%
Link
LONG
Oct 29. 2015
18.07
Nov 12. 2015
20.00
10 Trading Days
10.69%
Link
LONG
Dec 10. 2015
21.89
Dec 21. 2015
24.63
7 Trading Days
12.50%
Link
LONG
Feb 10. 2016
17.63
Feb 23. 2016
19.80
8 Trading Days
12.33%
Link
LONG
Sep 21. 2016
12.82
Oct 6. 2016
17.73
11 Trading Days
38.34%
Link
LONG
Jun 1. 2017
9.17
Jun 29. 2017
11.49
20 Trading Days
25.32%
Link
LONG
Oct 4. 2017
10.74
Oct 13. 2017
11.42
7 Trading Days
6.37%
Link
Company Information
Stock Symbol
COLL
Exchange
NasdaqGS
Company URL
http://http://www.collegiumpharma.com
Company Phone
781-713-3699
CEO
Michael Thomas Heffernan
Headquarters
Massachusetts
Business Address
780 DEDHAM STREET, SUITE 800, CANTON, MA 02021
Sector
Equity
Industry Category
Drugs
Industry Group
Drugs - Generic
CIK
0001267565
About

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases.

Description

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases. Its lead product candidate is Xtampza, an oral formulation of oxycodone. The company is also developing COL-195, a hydrocodone for the treatment of chronic pain; COL-172, an oxymorphone for the treatment of chronic pain; COL-196, a morphine formulation to treat pain; and COL-171, a proprietary preclinical DETERx methylphenidate formulation for the treatment of attention deficit hyperactivity disorder. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Canton, Massachusetts.